May 6th 2022
An expert in the lung cancer and a representative from lung cancer advocacy group talk about the use of amivantamab, a novel therapy approved for treating EGFR exon 20 insertion–positive disease.
A brief discussion on the importance of accessing novel therapy and clinical trials in the setting of EGFR exon 20 insertion–positive NSCLC.
May 5th 2022
Mental wellbeing is more of a focus than ever before in cancer care, and while treatments continue to get better, there is still a long road ahead, according to Patrick Dempsey.
Bryan Lewis, president of KidneyCAN, and Chung-Han Lee, MD, describe unmet needs and future perspectives in the treatment of renal cell carcinoma.
Meryl Uranga describes her path with metastatic clear cell renal cell carcinoma after first treatment, and how it has affected her outlook on her life and future.
A look at how to consider quality-of-life clinical trial and patient-reported data when treating clear cell renal cell carcinoma with combination therapies.
A brief discussion on therapeutic options one may consider after progression on lenvatinib therapy for iodine-refractory DTC.
Shared practical advice for patients who may be undergoing treatment for iodine-refractory differentiated thyroid cancer.
May 2nd 2022
Meryl Uranga describes her personal experience with managing the side effects of treatment for clear cell renal cell carcinoma.
An overview of side effects commonly seen with lenvatinib plus pembrolizumab for the treatment of clear cell renal cell carcinoma.
May 1st 2022
Watch Dr. Thomas Hutson, Dr. Saby George, Dr. Jeff Yorio and Louise Gunter answer questions about combination therapy, during the CURE Educated Patient Kidney Cancer Summit.
April 30th 2022
Watch Louise Gunter, from Texas Oncology, discuss IO/TKI-related side effects, during the CURE Educated Patient Kidney Cancer Summit.
April 29th 2022
Shared insight on how molecular profiling can impact the management of EGFR exon 20 insertion–positive NSCLC and how patient advocacy groups can help patients to interpret test results.
Experts explain the presence and role of EGFR exon 20 insertion mutations in non–small cell lung cancer and highlight the role of molecular profiling.
Watch Dr. Jeff Yorio, from Texas Oncology, discuss treatment with the combination of immunotherapy and tyrosine kinase inhibitors, during the CURE Educated Patient Kidney Cancer Summit.
April 28th 2022
Watch Dr. Saby George, from Roswell Park Comprehensive Cancer Center, discuss treatment with the combination of immunotherapies, during the CURE Educated Patient Kidney Cancer Summit.
Discussion on how best to communicate with care providers while undergoing therapy for iodine-refractory differentiated thyroid cancer.
Considerations for how dosing and dose reductions can be used to optimize use of lenvatinib for iodine-refractory DTC.
April 27th 2022
Watch Dr. Thomas Hutson, Louise Gunter and Meryl Uranga discuss communicating with a care team about treatment with immunotherapy combined with tyrosine kinase inhibitors, during the CURE Educated Patient Kidney Cancer Summit.
April 26th 2022
Watch Dr. Thomas Hutson, Louise Gunter and Meryl Uranga discuss side effects and dose reductions after treatment with immunotherapy combined with tyrosine kinase inhibitors, during the CURE Educated Patient Kidney Cancer Summit.
April 25th 2022
Watch Dr. Thomas Hutson, Louise Gunter and Meryl Uranga discuss the treatment of combining immunotherapy with tyrosine kinase inhibitors, during the CURE Educated Patient Kidney Cancer Summit.
April 24th 2022
Watch Dr. Thomas Hutson, Dr. Jose Karam, Dr, Naomi Haas, and Kiran Kehoe answer questions about frontline therapy during the CURE Educated Patient Kidney Cancer Summit.
April 23rd 2022
Watch Dr. Naomi Haas, from Abramson Cancer Center, discuss adjuvant therapy options, during the CURE Educated Patient Kidney Cancer Summit.
April 22nd 2022
Watch Dr. Jose Karam, from The University of Texas MD Anderson Cancer Center, discuss surgical options, during the CURE Educated Patient Kidney Cancer Summit.
April 21st 2022
Clinical nurse Kiran Virdee explains why a multidisciplinary treatment approach to clear cell renal cell carcinoma is beneficial.
An oncologist describes the necessity of discussing options with a patient when picking a treatment approach for clear cell renal cell carcinoma.
Expert and patient perspectives on receiving lenvatinib therapy for iodine-refractory differentiated thyroid cancer.
Watch Dr. Vitaly Margulis, Dr. Rana Mckay and Kwame Garrett-Price answer questions about kidney cancer diagnoses during the CURE Educated Patient Kidney Cancer Summit.
Health care specialists share insight on the work-up of patients with iodine-refractory differentiated thyroid cancer and how this may affect systemic therapy options.
April 20th 2022
By understanding what a TNM staging score is, patients and clinicians can determine the best line of treatment for their kidney cancer, as well as what the survivorship care plan should be.
Cancer Causes Me to Live Life With Uncertainty
A Ray of Sunshine on the Oncology Ward
During Cancer, I Find My Inner Goddess With Dinosaurs and Old Movies
Mike Peters of The Alarm Faces Cancer With Rock Optimism on New Album